DOI: https://doi.org/10.36347/sasjm.2024.v10i12.006

Pages: 1388-1392

Colorectal cancer, is the third most common cancer. 19% of patients have metastatic disease at the time of diagnosis. Half of the patients have risk of distant metastasis during their lives. New drugs were added in recent years, but it was limited fifteen years ago. In this study demographic parameters, treatment options, effects on overall survival of 172 patients with mCRC followed by Medical Oncology Department were examined. 110 patients(64%) had metastasis at diagnosis, 62(36%) had metastasis thereafter. Liver was the most common site(107 patients %62,2). 16 patients(9,3%) had metastasectomy. 104 patients(59,3%) had one; 49(28,5%) had two and 21(12,2%) had three lines of chemotherapy. Life expectancy was found to be increased as the number of line of chemotherapy increased. 44 patients(25,6%) had FOLFOX therapy, 52(30,2%) had IFL, 39 patients(22,7%) had a combination of bevacizumab and FOLFIRI and 37(%21,5) had XELOX. Overall survival rates were not different when treatment regimes were considered(Log rank:6,668; p:0,083;p>0,05). Most important factor at choosing the chemotherapy regime’s the evaluation of possible side effects. This hypothesis is supported with our study in which patients with higher performance status had second and third line treatments.